Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Pharmacol Ther. 2017 Jul 16;181:22–33. doi: 10.1016/j.pharmthera.2017.07.008

Figure 3.

Figure 3

The metabolic events leading to altered very-low density lipoprotein (VLDL) secretion in NAFLD. While increased synthesis of ApoB100 leads to enhanced VLDL secretion in steatosis, oxidative stress-induced degradation of ApoB100 may result in reduced VLDL secretion in NASH. TG; triglyceride, ROS; reactive oxygen species, FAO; fatty acid oxidation.